Semaglutide biosimilar(Heze Pharmaceutical)

司美格鲁肽生物类似药（和泽医药）

Report date: 2022/03/30 14:14:05

Base Information

Drug NameSemaglutide biosimilar(Heze Pharmaceutical)
Drug Alias Namesemaglutida biosimilar索马鲁肽生物类似药semaglutidum biosimilar索玛鲁肽生物类似药司美鲁肽生物类似药 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Heze Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Heze Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A